JOURNAL OF VIROLOGY, Sept. 2009, p. 8463–8469 Vol. 83, No.

17
0022-538X/09/$08.00⫹0 doi:10.1128/JVI.00751-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Inhibition of Intrahepatic Gamma Interferon Production by Hepatitis C

Virus Nonstructural Protein 5A in Transgenic Mice䌤
Tatsuo Kanda,1† Robert Steele,1 Ranjit Ray,2,3 and Ratna B. Ray1,2,3*
Departments of Pathology1 and Internal Medicine2 and Liver Center,3 Saint Louis University, St. Louis, Missouri
Received 12 April 2009/Accepted 18 June 2009

Hepatitis C virus (HCV) utilizes strategies to suppress or evade the host immune response for establishment
of persistent infection. We have shown previously that HCV nonstructural protein 5A (NS5A) impairs tumor
necrosis factor alpha (TNF-␣)-mediated apoptosis. In this study, we have examined the immunomodulatory
role of HCV NS5A protein in transgenic mouse (NS5A-Tg) liver when mice were challenged with an unrelated
hepatotropic adenovirus as a nonspecific stimulus. Hepatotropic adenovirus was introduced intravenously into
NS5A-Tg mice and control mice, and virus clearance from liver was compared over a time course of 3 weeks.

Downloaded from http://jvi.asm.org/ on May 24, 2017 by guest

The differential mRNA expression levels of 84 cytokine-related genes, signal pathway molecules, transcription
factors, and cell surface molecules were determined using real-time reverse transcription-PCR array. NS5A-Tg
mice failed to clear adenovirus from liver up to 3 weeks postinfection while control mice cleared virus within
1 to 2 weeks. Subsequent study revealed that gamma interferon (IFN-␥) expression is inhibited at both the
mRNA and protein levels in NS5A-Tg mice, and an inverse expression of transcription factors Gata-3 and
Tbx21 is observed. However, TNF-␣ mRNA and protein expression were elevated in both NS5A-Tg and control
mice. Together, our results suggested that HCV NS5A acts as an immunomodulator by inhibiting IFN-␥
production and may play an important role toward establishment of chronic HCV infection.

Hepatitis C virus (HCV), a member of Flaviviridae, causes
chronic infection associated with cirrhosis and hepatocellular
carcinoma. The HCV genome containing positive-strand RNA
is approximately 9.6 kb and encodes a polyprotein precursor of
about 3,000 amino acids, which is cleaved by both viral and
host proteases into structural (core, E1, E2, and p7) and non-
structural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) pro-
teins. HCV NS5A exists as two phosphoproteins, p56 and p58,
phosphorylated at serine residues after the mature protein is
released from the polyprotein (46). HCV NS5A has an anti-
apoptotic effect (11, 27) and modulates immune responses
(1, 39).
Interferons (IFNs) are key players of the innate immune
response to virus infection. alpha IFN (IFN-␣) and IFN-␤
(type I IFNs) are secreted by almost all virus-infected cells and
by specialized blood lymphocytes. In contrast, the production
of IFN-␥ (type II IFN) is restricted to cells of the immune
system, such as natural killer (NK) cells, macrophages, and T
cells. Although the antiviral effect of type I IFN on the repli-
cation of HCV has been the subject of extensive research and
although the endogenous type I IFN antiviral effector pathway
is known to be broadly activated during chronic HCV disease
(25), little is known about the role of other cytokines in cellular
defense against HCV. Further, how HCV manages to evade
the host defense is poorly understood.
In the liver of chimpanzees acutely infected with HCV,
IFN-␥ was detected only in animals displaying sustained or
* Corresponding author. Mailing address: Department of Pathology,
Saint Louis University, 1100 S. Grand Blvd., DRC-207, St. Louis, MO
63104. Phone: (314) 977-7822. Fax: (314) 771-3816. E-mail: rayrb@slu
.edu.
† Present address: Chiba University, School of Medicine, Chiba,
Japan.
䌤
Published ahead of print on 24 June 2009.
transient viral clearance in the context of an intrahepatic HCV-
specific T-cell response (26, 41, 47, 52). An increase in the
IFN-␥ gene was not detected by microarray or by quantitative
PCR in the liver of chimpanzees chronically infected with
HCV compared with HCV-uninfected chimpanzees (4, 16).
IFN-␥ mRNA expression levels in peripheral blood mononu-
clear cells of patients are significantly lower in nonresponders
(15). During the first 6 months of onset of HCV infection, the
number of IFN-␥-producing HCV-specific CD8⫹ T cells is
associated with virus eradication (13). IFN-␥ also inhibits HCV
genome replication in vitro (9). On the other hand, tumor
necrosis factor alpha (TNF-␣), a primary initiator of innate
immune response, determines the magnitude and course of
acquired immune responses. TNF-␣-induced apoptosis is im-
portant for clearance of virus-infected cells, and IFN-␥ accel-
erates the killing of virus-infected cells (17, 32, 48, 52).
A number of viruses have been shown to encode proteins
that have the potential to inhibit antiviral activity of innate and
adaptive immune responses. Inflammatory cytokines contrib-
ute to viral clearance during acute viral hepatitis in humans,
and the induction of these cytokines in the liver and other
tissues of chronically infected patients may have therapeutic
value (20). Disson et al. (8) have shown that transgenic mice
expressing HCV polyprotein failed to clear an adenoviral in-
fection. However, transgenic mice expressing either core or
structural proteins do not appear to be immunologically
impaired as they are fully competent to eliminate hepato-
cytes infected with adenovirus (Ad) (24, 42). Together,
these results suggest a role of HCV nonstructural protein(s)
in the modulation of the immune system. In this present
study, we have examined the role of HCV NS5A protein on
intrahepatic cytokine production for clearance of an unre-
lated hepatotropic Ad using a transgenic mouse model. Our
results demonstrated that IFN-␥ production is inhibited and

8463
8464 KANDA ET AL. J. VIROL.

that Ad clearance is impaired in NS5A-transgenic (NS5A-

Tg) mouse liver.

MATERIALS AND METHODS

HCV NS5A-Tg mice. Transgenic FVB mice were generated by targeting the
HCV NS5A genomic region from genotype 1a, cloned under the control of a
mouse major urinary promoter in the hepatocytes (29). The major urinary pro-
moter is developmentally regulated and expressed in the liver after birth. These
mice express HCV NS5A in the liver, are phenotypically similar to their normal
littermates, and do not exhibit detectable histological changes in liver for 6 to 24
months. The expression of the transgene was comparable to that in HCV-
infected liver in humans (29). NS5A-Tg mice or control (nontransgenic [NTg])
mice aged 10 to 12 weeks were used in this study.
Ad infection. A recombinant replication-deficient Ad designated AdGFP was
kindly provided by Bert Vogelstein (Johns Hopkins University, Baltimore, MD).
This virus system is based on the human Ad type 5 from which the E1a and E1b
genes were deleted and is capable of infecting murine hepatocytes. Infecting cells
with AdGFP expresses green fluorescent protein (GFP) under the control of a

Downloaded from http://jvi.asm.org/ on May 24, 2017 by guest

cytomegalovirus promoter. Stocks of AdGFP were grown in 293 cells and purified by
two rounds of CsCl density gradient centrifugation as described previously (10).
Virus titers were determined by plaque assay on 293 cells, and a single stock was used
throughout this study. Mice (12 in each group and for each time point) were injected
with a single dose of AdGFP (1.0 ⫻ 109 PFU/mouse) or with 100 ␮l of saline as
control via tail vein. Infected mice were sacrificed at the time points indicated in Fig.
1. Livers were frozen with optimal cutting temperature medium for histological
examination and snap frozen for RNA or protein analysis.
GFP expression in AdGFP-infected mouse liver. Cryostat-frozen liver sections
(5 ␮m) were examined by indirect fluorescence microscopy for in vivo expression
of GFP in AdGFP-infected mouse liver (Bio-Rad 1024; Bio-Rad Laboratories,
Hercules, CA). One or two slides were examined for each liver specimen. GFP
expression was also quantitated using a fluorometer (1420 Victor Multilabel
Counter; Perkin Elmer, Wellesley, MA) as described earlier (2). We also exam-
ined GFP expression using immunoblot analysis. Proteins were subjected to
electrophoresis on a 12% polyacrylamide gel and transferred onto a nitro-
cellulose membrane (Bio-Rad). The membrane was probed with a monoclo-
nal antibody to GFP or ␤-tubulin (Santa Cruz Biotechnology, Santa Cruz,
CA). Protein bands were visualized using enhanced chemiluminescence
(Pierce, Rockford, IL).
ELISA. Mouse sera were analyzed for circulating IFN-␥ and TNF-␣ using an
enzyme-linked immunosorbent assay (ELISA; R & D System, Minneapolis, MN)
following the manufacturer’s protocol. Briefly, serum samples were incubated in
plates at 4°C overnight, followed by incubation with biotinylated monoclonal
antibodies. Avidin-conjugated peroxidase was added to the plates, and enzyme
activity was detected with an ELISA plate reader.
RNA extraction and real-time PCR. Total RNA was extracted from mouse FIG. 1. Impaired clearance of Ad from NS5A-Tg mouse liver.
liver (day 14 after Ad infection) using a Purescript RNA isolation kit (Gentra (A) NTg (panels a, c, e, and g) and NS5A-Tg mice (panels b, d, f, and
Systems, Minneapolis, MN). We isolated RNA from individual livers of six mice h) were infected with replication-deficient recombinant Ad expressing
(i.e., not pooled samples) from each group. Each mouse liver RNA sample was GFP by injection through the tail vein (1 ⫻ 109 PFU). Mice were
used in each PCR array. cDNA synthesis was performed using a random hex- sacrificed at day 3 (a and b), day 7 (c and d), day 14 (e and f), or day
amer. Comparison of the relative expression levels of 84 inflammatory cytokines 21 (g and h), and liver sections were evaluated microscopically for GFP
and T-cell marker-related genes was performed with a mouse PCR array (Su- expression. (B) GFP expression was quantitated from the crude liver
perarray Bioscience Corporation, Frederick, MD). For RNA quantitation, real- extracts of NS5A-Tg and NTg mice at different days. GFP expression
time PCR was conducted using SYBR Green I (ABI Prism 7700; Applied from day 3 postinfection mouse liver was chosen arbitrarily as 100%.
Biosystems, Foster City, CA). The two housekeeping genes (glyceraldehyde-3- (C) GFP expression from liver extracts (day 21) of NS5A-Tg and NTg
phosphate dehydrogenase and actin) were used for normalization, and data were mice was analyzed using specific antibody. The blot was reprobed with
analyzed by the comparative threshold cycle (CT) method. We have done the an antibody to ␤-tubulin for comparison of protein load.
assay on day 14 from each group following Ad infection. Relative quantification
of gene expression using the 2⫺⌬⌬Ct method correlated with the absolute gene
quantification obtained using a standard curve (40). Data were analyzed with
RT2 profiler PCR array data analysis software (http://www.superarray.com
and NTg mice (12 in each group) were injected with ⬃1 ⫻ 109
/pcrarraydataanalysis.php). Genes were annotated using Mouse Genome Infor-
matics (http://www.informatics.jax.org/). The relative differences were calculated PFU of AdGFP via tail vain. Livers were collected from mice
by comparing untreated mice with day 14 Ad-infected mice, and results were at 3, 7, 14, and 21 days postinfection. Recombinant Ad infec-
then compared between normal and transgenic mouse groups. tion was monitored from GFP marker expression. Hepatocytes
(⬎95%) displayed GFP expression from the recombinant Ad
in NS5A-Tg and NTg mouse livers at day 3 (Fig. 1A). GFP-
RESULTS
positive cells were also readily detectable at days 7, 14, and 21
Impaired clearance of Ad from HCV NS5A-Tg mouse liver. following Ad infection in NS5A-Tg mouse livers in contrast to
To investigate the effect of HCV NS5A on unrelated virus the NTg controls. Liver extracts were prepared from both
clearance from mouse liver, age- and sex-matched NS5A-Tg NS5A-Tg and NTg mice at days 3, 7, 14, and 21 as described
VOL. 83, 2009 HCV NS5A INHIBITS INTRAHEPATIC IFN-␥ PRODUCTION
FIG. 2. Liver specimens from day 7 Ad-infected NTg and NS5A-Tg mice were immunostained with CD3⫹ antibody and counterstained with
hematoxylin to determine infiltrating T cells (top panels). Liver sections were also stained with hematoxylin and eosin (H&E) to examine
inflammatory infiltrates and liver histopathology (bottom panels).
previously (28), and GFP expression was quantitated using a
fluorometer (Fig. 1B). GFP expression was normalized to that
from mouse livers on day 3. GFP expression was also examined
by Western blot analysis (Fig. 1C). Together, our results re-
vealed that the NS5A-Tg mice fail to clear Ad from liver up to
21 days postinfection.
We have examined the T-cell infiltration in both NTg and
NS5A-Tg mice at day 7 following Ad infection. For this, the
presence of CD3⫹ cells was examined in liver sections by
immunohistochemistry. Slides were immunostained with anti-
CD3 antibody and counterstained with hematoxylin. CD3⫹
cells from at least five fields of each slide were counted in a
blinded manner. We did not observe a significant difference in
the level of CD3 marker between the NS5A-Tg and NTg mice
(Fig. 2). The slides were also stained with hematoxylin and
eosin to examine inflammation. We have observed a slightly
higher level of inflammation in NTg mice than in HCV
NS5A-Tg mice following Ad infection. A representative illus-
tration is shown in Fig. 2 (bottom panel). Our results are in
agreement with the earlier study of transgenic mice expressing
the entire HCV genome (8), suggesting that the presence of
the HCV transgene does not impair intrahepatic T-cell infil-
tration. We also examined the alanine aminotransferase
(ALT) level from serum of NS5A-Tg and NTg mice at different
time points. The ALT level was increased approximately five-
to eightfold on day 7 and day 14 in NTg mice compared to
levels in NS5A-Tg mice (Table 1).
8465
Downloaded from http://jvi.asm.org/ on May 24, 2017 by guest
Intrahepatic cytokine gene expression during Ad infection in
HCV NS5A-Tg mice. CD4⫹ T cells are a major player in the
induction of protective immune response to HCV infection.
Th17 is a newly defined subset of CD4⫹ T cells. The discovery
of the Th17 lineage has revealed additional complexity in the
fates chosen by helper T cells and has begun to reshape our
view of how signaling and transcriptional networks generate
appropriate and inappropriate immunity (37). We have exam-
ined cytokine-related gene expression profiles using real-time
PCR-based focused microarrays for intrahepatic inflammatory
genes related to the Th17 regulatory network. A comparison of
intrahepatic cytokines between NS5A-Tg and NTg mice at day
14 of Ad infection is shown in Fig. 3A. Out of 84 cytokine-
related genes examined, 63 (75.0%) were upregulated by 2.0-
TABLE 1. Serum ALT level in NTg and NS5A-Tg mice
Time point ALT level (U/liter)a
(day) NTg mice NS5A-Tg mice
0 120 ⫾ 31 122 ⫾ 23
7 696 ⫾ 218 188 ⫾ 65
14 1071 ⫾ 206 298 ⫾ 104
24 ND 144 ⫾ 56
a
Data for each time point represent the sera of six animals, and values are
means ⫾ standard deviations. ND, not done (AdGFP was cleared from mouse
liver).
8466 KANDA ET AL.
FIG. 3. Differential expression of intrahepatic cytokine genes in
NS5A-Tg and NTg mice following Ad infection. (A) NTg and
NS5A-Tg mice were infected with Ad or left untreated. Liver RNA
was isolated at day 14 postinfection and used in focused microarray
analysis for 84 genes. All gene expression levels were corrected by
comparison with the level of two housekeeping genes (glyceralde-
hyde-3-phosphate dehydrogenase and actin) and compared. Six sets
of real-time PCR arrays were performed, and the results were
analyzed using RT2 profiler PCR array data analysis software (Su-
perarray). (B) The details of genes upregulated 2.0-fold or greater
in NTg mice and HCV NS5A-Tg mice are shown.
fold or greater in NTg mice while 38 (45%) genes were up-
regulated 2.0-fold or higher in NS5A-Tg mice (Fig. 3B). The
response to Ad infection was partly related to NS5A expres-
sion, with 32 genes unique to the NTg mice, 7 unique to
NS5A-Tg mice, and 31 expressed in both NS5A-Tg and NTg
mice. Eleven genes (TNF-␣, interleukin-23 receptor [IL-23R],
CCL20, granulocyte colony-stimulating factor, IL-21, CXCL5,
IL-12RB2, IL-10, IFN-␥, Toll-like receptor 4 [TLR4], and IL-
17␣) were upregulated fivefold or more in NTg mice, and only
TNF-␣ was upregulated in NS5A-Tg mice following Ad infec-
tion. The results of the genes upregulated twofold or greater
are summarized in Fig. 3. On the other hand, out of 84 genes,
5 (5.9%) genes were downregulated 2.0-fold or more in both
groups of mice (Fig. 3A). Among these, four genes were
unique to the NTg mice (IL-17, PBST-1, PB1, and calcyclin
binding protein) and NS5A-Tg mice (IL-23, CD127, NF-E1,
and Stat3), and one gene was expressed in both types of mice.
CCAAT/enhancer binding protein beta, which has antiapop-
totic function, was the only gene downregulated in both animal
groups.
Further analysis revealed that among the Th1 cytokines,
IFN-␥, granulocyte colony-stimulating factor, and IL-2 mRNA
expression levels were suppressed significantly in NS5A-Tg
mice compared to NTg control mice (Fig. 4A). On the other
hand, TNF-␣ and IL-12␤ mRNA inductions were similar in
J. VIROL.
Downloaded from http://jvi.asm.org/ on May 24, 2017 by guest
FIG. 4. Differential expression of intrahepatic cytokine mRNA lev-
els (A) and presence of lymphoid cell markers (B) in Ad-infected the
liver of NTg and NS5A-Tg mice. Gene expression was measured by
quantitative real-time PCR, and results are presented as induction
relative to basal levels in each of the uninfected mice. Six mice in each
group were examined.
both NS5A-Tg and NTg mice infected with Ad (Fig. 4A).
Expression of chemokine genes, CCL7 (MCP-3) and CX3CR1,
was upregulated to approximately 2.0-fold in NS5A-Tg mice.
Importantly, CCL7 has been implicated with portal inflamma-
tion in liver disease (49) while CX3CR1 is involved in liver
fibrosis due to chronic HCV infection (51).
Ad-infected NS5A-Tg mice display altered expression of
intrahepatic lymphoid cell markers. One of the earliest mani-
festations of a cell-mediated immune response in the infected
liver is an increase in lymphoid cells. To examine cell infiltra-
tion, liver from mice injected with Ad was harvested and ana-
lyzed for lymphoid cell surface molecules using real-time PCR
(Fig. 4B.). Among the T-cell markers, the greatest suppression
was seen in CD8␣ (synonymous for CD8 in human) mRNA,
while CD4 mRNA was suppressed to a smaller extent in
NS5A-Tg animals. Among the B-cell markers, CD40lg was
suppressed in NS5A-Tg animals (Fig. 4B). ICAM-1, a well-
known cell adhesion molecule, was upregulated in NS5A-Tg
mice. Expression of Gata-3, Stat6, Socs3, Syk, Socs1, Jak1,
Myd88, TLR4, Stat4 and T-bet were upregulated ⱖ2.0-fold in
NS5A-Tg mouse livers. Therefore, these results suggested that
NS5A-Tg mouse liver exhibits decreased expression of CD4
and CD8 cell surface molecules. This could be the result of the
impact of NS5A expression on the overall ratio of CD4 to CD8
cells and awaits further in-depth analysis. An inverse expres-
sion of IFN-␥ and TLR in NS5A-Tg mouse liver is in agree-
ment with chronically infected HCV individuals who failed to
respond to IFN therapy (14). Tbx21 modulates IFN-␥ expres-
sion in Th1 cells (45). Our results suggested that Tbx21 mRNA
expression is suppressed in Ad-infected NS5A-Tg mice. This
VOL. 83, 2009
FIG. 5. Ad infection in NS5A-Tg mice does not enhance IFN-␥
secretion. IFN-␥ and TNF-␣ levels were determined by ELISA using
sera from NTg and NS5A-Tg mice. *, P ⬍ 0.001 by the Student’s t test
from comparison between sera of NTg and NS5A-Tg mice.
result is in agreement with the previous observation that the
Tbx21 mRNA level is reduced in HCV-infected T cells (19).
Ad infection of NS5A-Tg mice does not enhance IFN-␥ se-
cretion. TNF-␣ determines the magnitude and course of ac-
quired immune responses. TNF-␣-induced apoptosis is impor-
tant for lysis of virus-infected cells, and the activity of killing
virus-infected cells is accelerated by IFN-␥ (17, 32, 53). Mod-
ulation of TNF-␣ and IFN-␥ has been observed in HCV-in-
fected patients (16). Since IFN-␥ and TNF-␣ have also been
implicated in clearance of Ad from mouse liver (17, 43), the
modulation of these two cytokines involved in innate signaling
of NS5A-Tg mice was verified at the protein level by ELISA.
Our results demonstrated that TNF-␣ expression was upregu-
lated in both NTg and NS5A-Tg mice (Fig. 5). On the other
hand, IFN-␥ production was significantly lower in Ad-infected
NS5A-Tg mice. These results are in agreement with our quan-
titative reverse transcription-PCR data described above and
the observations from chronically HCV-infected humans (35).
DISCUSSION
We have examined whether HCV NS5A interferes with the
innate antiviral signaling pathway in liver. For this, unrelated
hepatotropic Ad clearance from NS5A-Tg mouse liver was
investigated. The Ad-dependent antiviral effect occurs in two
distinct phases and has been eloquently described by Ca-
vanaugh et al. (5). The first phase of induction occurs within 12
to 24 h of infection and is mediated by IFN-␣/␤. The second
phase occurs after 3 to 7 days of infection and is associated
with intrahepatic induction of IFN-␣/␤ and TNF-␣ as well as
IFN-␥ for induction of the cellular immune response to the
invading virus. The production of these cytokines was also seen
in human infection from Ad and plays an important role in
viral clearance (30, 33, 43). An earlier report suggested that
transgenic mice expressing the entire HCV genome delay Ad
clearance from liver (8). On the other hand, mice expressing
HCV structural proteins do not impair Ad clearance (24, 42).
Here, we have shown that NS5A-Tg mice modulate the innate
immune response in the liver and impair Ad clearance. Inter-
estingly, both NTg and NS5A-Tg mice displayed elevation of
TNF-␣ while the level of IFN-␥ was significantly lower in
NS5A-Tg mice following Ad infection. However, HCV NS5A
blocks TNF-␣-mediated apoptosis (29), and a high level of
HCV NS5A INHIBITS INTRAHEPATIC IFN-␥ PRODUCTION 8467
Downloaded from http://jvi.asm.org/ on May 24, 2017 by guest
FIG. 6. A schematic diagram depicting the highlights of observa-
tions following Ad challenge in NTg and NS5A-Tg mice.
TNF-␣ expression is observed in the liver of chronically HCV-
infected individuals (22). Together, our results suggested that
inhibition of IFN-␥ expression in NS5A-Tg mice and blockade
of TNF-␣-mediated apoptosis by NS5A contribute to delayed
Ad clearance. IFN-␥ is not expressed in hepatocytes, and we
therefore believe that a secondary event may modulate IFN-␥
production since other resident cells cross talk in the liver.
IFN-␥ with potential antifibrotic action is associated with the
blockage of stellate cell activation, proliferation, and synthesis
of collagen. Experimental studies have demonstrated that
IFN-␥ inhibits extracellular matrix mRNA expression (47).
Suppression of IFN-␥ by NS5A may also be associated with the
progression of hepatic fibrosis in chronically infected HCV
patients. Our data support the earlier observation that patients
with self-limited hepatitis C display the strongest virus-specific
CD4⫹ T-cell (IFN-␥) reactivity while persistently infected sub-
jects initially show a weak antiviral CD4⫹ T-cell (IFN-␥) re-
sponse (14). We did not observe significant poly(ADP-ribose)
polymerase cleavage in Ad-infected NS5A-Tg mouse liver ex-
tract, suggesting an absence of apoptosis.
Gata-3 is essential for NK cell homing to the liver. While
Gata-3 antagonizes IFN-␥ production in differentiating T cells,
Gata-3-deficient NK cells paradoxically produce less IFN-␥
than control NK cells (37, 38). Gata-3 serves as a principal
switch in determining Th1/Th2 responses (54). Optimal induc-
tion of IFN-␥ expression also requires genetic interaction be-
tween Tbx21 (T-bet) and its target, the homeoprotein Hlx (34).
Tbx21 expression correlates with IFN-␥ expression in Th1 and
NK cells (45). Tbx21 mRNA was 2.2-fold upregulated in
NS5A-Tg mice and 8.7-fold upregulated in NTg mice following
Ad infection. These results are in agreement with the obser-
vation that the Tbx21 mRNA level is suppressed in HCV-
infected T cells (19). Tbx21 is required for protection against
human viral infection (6, 21, 31, 44). The principal function of
Tbx21 in developing Th1 cells is to negatively regulate Gata-3
(50). T lymphocytes have an essential role in the clearance of
acute HCV infection (7, 23). Individuals who are able to suc-
cessfully clear HCV seem to have not only specific but also
8468 KANDA ET AL.
broad cellular Th1-dominant responses. Abundant evidence
indicates that the immune system fails to eliminate virus from
the liver in a large number of HCV-infected patients, and as a
result, most acute infections lead to long-term viral persistence
(12, 36). The efficacies of therapeutic vaccination for chronic
hepatitis C nonresponder patients are correlated with the in-
hibition of IFN-␥ secretion (3, 18, 34). Our results revealed
that HCV NS5A affects Gata-3 and Tbx21 expression and
impairs IFN-␥ production (Fig. 6), thus contributing to viral
persistence.
ACKNOWLEDGMENTS
We thank Brendan Kappas for PCR arrays and John E. Sagartz for
helping us to evaluate the immunohistochemistry slides.
This work was supported by research grants AI45144 and AI065535
(R.B.R.) from the National Institutes of Health and by the Blue Rib-
bon Fund from Saint Louis University.
REFERENCES
1. Abe, T., Y. Kaname, I. Hamamoto, Y. Tsuda, X. Wen, S. Taguwa, K. Mori-
ishi, O. Takeuchi, T. Kawai, T. Kanto, N. Hayashi, S. Akira, and Y. Mat-
suura. 2007. Hepatitis C virus nonstructural protein 5A modulates the Toll-
like receptor–MyD88-dependent signaling pathway in macrophage cell lines.
J. Virol. 81:8953–8966.
2. Abougergi, M. S., S. J. Gidner, D. K. Spady, B. C. Miller, and D. L. Thiele.
2005. Fas and TNFR1, but not cytolytic granule-dependent mechanisms,
mediate clearance of murine liver adenoviral infection. Hepatology 41:97–
105.
3. Alvarez-Lajonchere, L., N. H. Shoukry, B. Gra, Y. Amador-Canizares, F.
Helle, N. Bedard, I. Guerra, C. Drouin, J. Dubuisson, E. E. Gonzalez-Horta,
G. Martinez, J. Marante, Z. Cinza, M. Castellanos, and S. Duenas-Carrera.
2009. Immunogenicity of CIGB-230, a therapeutic DNA vaccine prepara-
tion, in HCV-chronically infected individuals in a Phase I clinical trial. J.
Viral Hepat. 16:156–167.
4. Bigger, C. B., B. Guerra, K. M. Brasky, G. Hubbard, M. R. Beard, B. A.
Luxon, S. M. Lemon, and R. E. Lanford. 2004. Intrahepatic gene expression
during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78:13779–
13792.
5. Cavanaugh, V. J., L. G. Guidotti, and F. V. Chisari. 1998. Inhibition of
hepatitis B virus replication during adenovirus and cytomegalovirus infec-
tions in transgenic mice. J. Virol. 72:2630–2637.
6. Chen, R. F., J. W. Liu, W. T. Yeh, L. Wang, J. C. Chang, H. R. Yu, J. T.
Cheng, and K. D. Yang. 2005. Altered T helper 1 reaction but not increase
of virus load in patients with dengue hemorrhagic fever. FEMS Immunol.
Med. Microbiol. 44:43–50.
7. Day, C. L., G. M. Lauer, G. K. Robbins, B. McGovern, A. G. Wurcel, R. T.
Gandhi, R. T. Chung, and B. D. Walker. 2002. Broad specificity of virus
specific CD4⫹ T-helper-cell responses in resolved hepatitis C virus infection.
J. Virol. 76:12584–12595.
8. Disson, O., D. Haouzi, S. Desagher, K. Loesch, M. Hahne, E. J. Kremer, C.
Jacquet, S. M. Lemon, U. Hibner, and H. Lerat. 2004. Impaired clearance of
virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus
polyprotein. Gastroenterology 126:859–872.
9. Frese, M., K. Barth, A. Kaul, V. Lohmann, V. Schwarzle, and R. Barten-
schlager. 2002. Interferon-gamma inhibits replication of subgenomic and
genomic hepatitis C virus RNAs. Hepatology 35:694–703.
10. Ghosh, A. K., I. Grigorieva, R. Steele, R. G. Hoover, and R. B. Ray. 1999.
PTEN transcriptionally modulates c-myc gene expression in human breast
carcinoma cells and is involved in cell growth regulation. Gene 235:85–91.
11. Ghosh, A. K., M. Majumder, R. Steele, K. Meyer, R. Ray, and R. B. Ray.
2000. Hepatitis C virus NS5A protein protects against TNF-alpha mediated
apoptotic cell death. Virus Res. 67:173–178.
12. Graham, C. S., M. Curry, Q. He, N. Afdhal, D. Nunes, C. Fleming, R.
Horsburgh, D. Craven, K. E. Sherman, and M. J. Koziel. 2004. Comparison
of HCV-specific intrahepatic CD4⫹ T cells in HIV/HCV versus HCV. Hepa-
tology 40:125–132.
13. Gruner, N. H., T. J. Gerlach, M.-C. Jung, H. M. Diepolder, C. M. Schirren,
W. W. Schraut, R. Hoffmann, R. Zachoval, T. Santantonio, M. Cucchiarini,
A. Cerny, and G. R. Pape. 2000. Association of hepatitis C virus-specific
CD8⫹ T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 181:
1528–1536.
14. Guobuzaite, A., S. Chokshi, L. Balciūniene, A. Voinic, A. Stikleryte, K.
Zagminas, A. Ambrozaitis, and N. Naoumov. 2008. Viral clearance or per-
sistence after acute hepatitis C infection: interim results from a prospective
study. Medicina (Kaunas) 44:510–520.
15. He, Q., C. S. Graham, E. Durante Mangoni, and M. J. Koziel. 2006. Differ-
J. VIROL.
ential expression of toll-like receptor mRNA in treatment non-responders
and sustained virologic responders at baseline in patients with chronic hep-
atitis C. Liver Int. 26:1100–1110.
16. Huang, Y., J. J. Feld, R. K. Sapp, S. Nanda, J. H. Lin, L. M. Blatt, M. W.
Fried, K. Murthy, and T. J. Liang. 2007. Defective hepatic response to
interferon and activation of suppressor of cytokine signaling 3 in chronic
hepatitis C. Gastroenterology 132:733–744.
17. Kafrouni, M., G. R. Brown, and D. L. Thiele. 2003. The role of TNF-TNFR2
interactions in generation of CTL responses and clearance of hepatic ade-
novirus infection. J. Leukoc. Biol. 74:564–571.
18. Klade, C. S., H. Wedemeyer, T. Berg, H. Hinrichsen, G. Cholewinska, S.
Zeuzem, H. Blum, M. Buschle, S. Jelovcan, V. Buerger, E. Tauber, J. Frisch,
and M. P. Manns. 2008. Therapeutic vaccination of chronic hepatitis C
nonresponder patients with the peptide vaccine IC41. Gastroenterology 134:
1385–1395.
19. Kondo, Y., V. M. Sung, K. Machida, M. Liu, and M. M. Lai. 2007. Hepatitis
C virus infects T cells and affects interferon-gamma signaling in T cell lines.
Virology 361:161–173.
20. Koziel, M. J. 1999. Cytokines in viral hepatitis. Semin. Liver Dis. 19:157–169.
21. Kulkarni, A., D. S. Ravi, K. Singh, S. Rampalli, V. Parekh, D. Mitra, and S.
Chattopadhyay. 2005. HIV Tat modulates T-bet expression and induces Th1
type of immune response. Biochem. Biophys. Res. Commun. 329:706–712.
Downloaded from http://jvi.asm.org/ on May 24, 2017 by guest
22. Larrea, E., N. Garcia, C. Qian, M. P. Civeira, and J. Prieto. 1996. Tumor
necrosis factor alpha gene expression and the response to interferon in
chronic hepatitis C. Hepatology 23:210–217.
23. Lechner, F., D. K. Wong, P. R. Dunbar, R. Chapman, R. T. Chung, P.
Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B. D. Walker.
2000. Analysis of successful immune responses in persons infected with
hepatitis C virus. J. Exp. Med. 191:1499–1512.
24. Liu, Z.-X., H. Nishida, J.-W. He, M. M. C. Lai, N. Feng, and G. Dennert.
2002. Hepatitis C virus genotype 1b core protein does not exert immuno-
modulatory effects on virus-induced cellular immunity. J. Virol. 76:990–997.
25. MacQuillan, G. C., C. Mamotte, W. D. Reed, G. P. Jeffrey, and J. E. Allan.
2003. Upregulation of endogenous intrahepatic interaction stimulated genes
during chronic hepatitis C virus infection. J. Med. Virol. 70:219–227.
26. Major, M. E., H. Dahari, K. Mihalik, M. Puig, C. M. Rice, A. U. Neumann,
and S. M. Feinstone. 2004. Hepatitis C virus kinetics and host responses
associated with diseases and outcome of infection in chimpanzees. Hepatol-
ogy 39:1709–1720.
27. Majumder, M., A. K. Ghosh, R. Steele, R. Ray, and R. B. Ray. 2001. Hep-
atitis C virus NS5A physically associates with p53 and regulates p21/waf1
gene expression in a p53-dependent manner. J. Virol. 75:1401–1407.
28. Majumder, M., A. K. Ghosh, R. Steele, X. Y. Zhou, N. J. Phillips, R. Ray, and
R. B. Ray. 2002. Hepatitis C virus NS5A protein impairs TNF-mediated
hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice.
Virology 294:94–105.
29. Majumder, M., R. Steele, A. K. Ghosh, X. Y. Zhou, L. Thornburg, R. Ray,
N. J. Phillips, and R. B. Ray. 2003. Expression of hepatitis C virus non-
structural 5A protein in the liver of transgenic mice. FEBS Lett. 555:528–
532.
30. Matsubara, T., T. Inoue, N. Tashiro, K. Katayama, T. Matsuoka, and S.
Furukawa. 2000. Activation of peripheral blood CD8⫹ T cells in adenovirus
infection. Pediatr. Infect. Dis. J. 19:766–768.
31. Matsui, M., O. Moriya, T. Yoshimoto, and T. Akatsuka. 2005. T-bet is
required for protection against vaccinia virus infection. J. Virol. 79:12798–
12806.
32. Mestan, J., W. Digel, S. Mittnacht, H. Hillen, D. Blohm, A. Moller, H.
Jacobsen, and H. Kirchner. 1986. Antiviral effects of recombinant tumor
necrosis factor in vitro. Nature 323:816–819.
33. Mistchenko, A. S., R. A. Diez, A. L. Mariani, J. Robaldo, A. F. Maffey, G.
Bayley-Bustamante, and S. Grinstein. 1994. Cytokines in adenoviral disease
in children: association of interleukin-6, interleukin-8, and tumor necrosis
factor alpha levels with clinical outcome. J. Pediatr. 124:714–720.
34. Mullen, A. C., A. S. Hutchins, F. A. High, H. W. Lee, K. J. Sykes, L. A.
Chodosh, and S. L. Reiner. 2002. Hlx is induced by and genetically interacts
with T-bet to promote heritable TH1 gene induction. Nat. Immunol. 3:652–
658.
35. Neveu, B., E. Debeaupuis, K. Echasserieau, B. le Moullac-Vaidye, M. Gas-
sin, L. Jegou, J. Decalf, M. Albert, N. Ferry, J. Gournay, E. Houssaint, M.
Bonneville, and X. Saulquin. 2008. Selection of high-avidity CD8 T cells
correlates with control of hepatitis C virus infection. Hepatology 48:713–722.
36. Rahman, F., T. Heller, Y. Sobao, E. Mizukoshi, M. Nascimbeni, H. Alter, S.
Herrine, J. Hoofnagle, T. J. Liang, and B. Rehermann. 2004. Effects of
antiviral therapy on the cellular immune response in acute hepatitis C.
Hepatology 40:87–97.
37. Reiner, S. L. 2007. Development in motion: helper T cells at work. Cell
129:33–36.
38. Samson, S. I., O. Richard, M. Tavian, T. Ranson, C. A. Vosshenrich, F.
Colucci, F. J. Buer, F. Grosveld, I. Godin, and J. P. Di Santo. 2003. GATA-3
promotes maturation, IFN-gamma production, and liver-specific homing of
NK cells. Immunity 19:701–711.
39. Sarcar, B., A. K. Ghosh, R. Steele, R. Ray, and R. B. Ray. 2004. Hepatitis C
VOL. 83, 2009 HCV NS5A INHIBITS INTRAHEPATIC IFN-␥ PRODUCTION
virus NS5A mediated STAT3 activation requires co-operation of Jak1 ki-
nase. Virology 322:51–60.
40. Schmittgen, T. D., B. A. Zakrajsek, A. G. Mills, V. Gorn, M. J. Singer, and
M. W. Reed. 2000. Quantitative reverse transcription-polymerase chain re-
action to study mRNA decay: comparison of endpoint and real-time meth-
ods. Anal. Biochem. 285:194–204.
41. Su, A. I., J. P. Pezacki, L. Wodicka, A. D. Brideau, L. Supekova, R. Thimme,
S. Wieland, J. Bukh, R. H. Purcell, P. G. Schultz, and F. V. Chisari. 2002.
Genomic analysis of the host response to hepatitis C virus infection. Proc.
Natl. Acad. Sci. USA 99:15669–15674.
42. Sun, J., F. Bodola, X. Fan, H. Irshad, L. Soong, S. M. Lemon, and T. S.
Chan. 2001. Hepatitis C virus core and envelope proteins do not suppress the
host’s ability to clear a hepatic viral infection. J. Virol. 75:11992–11998.
43. Sung, R. S., L. Qin, and J. S. Bromberg. 2001. TNF␣ and IFN␥ induced by
innate anti-adenoviral immune responses inhibit adenovirus-mediated trans-
gene expression. Mol. Ther. 3:757–767.
44. Svensson, A., I. Nordstrom, J. B. Sun, and K. Eriksson. 2005. Protective
immunity to genital herpes simplex virus type 2 infection is mediated by
T-bet. J. Immunol. 174:6266–6273.
45. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H.
Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage
commitment. Cell 100:655–669.
46. Tanji, Y., T. Kaneko, S. Satoh, and K. Shimotohno. 1995. Phosphorylation of
hepatitis C virus-encoded nonstructural protein NS5A. J. Virol. 69:3980–
3986.
47. Teixeira, R., L. A. Marcos, and S. L. Friedman. 2007. Immunopathogenesis
8469
of hepatitis C virus infection and hepatic fibrosis: new insight into antifibrotic
therapy in chronic hepatitis C. Hepatol. Res. 37:579–595.
48. Thimme, R., J. Bukh, H. C. Spangenberg, S. Wieland, J. Pemberton, C.
Steiger, S. Govindarajan, R. H. Purcell, and F. V. Chisari. 2002. Viral and
immunological determinants of hepatitis C virus clearance, persistence, and
disease. Proc. Natl. Acad. Sci. USA 99:15661–15668.
49. Tsuneyama, K., K. Harada, M. Yasoshima, K. Hiramatsu, C. R. Mackay,
I. R. Mackay, M. E. Gershwin, and Y. Nakanuma. 2001. Monocyte chemo-
tactic protein-1, -2, and -3 are distinctively expressed in portal tracts and
granulomata in primary biliary cirrhosis: implications for pathogenesis.
J. Pathol. 193:102–109.
50. Usui, T., J. C. Preiss, Y. Kanno, Z. J. Yao, J. H. Bream, J. J. O’Shea, and W.
Strober. 2006. T-bet regulates Th1 responses through essential effects on
GATA-3 function rather than on IFNG gene acetylation and transcription.
J. Exp. Med. 203:755–766.
51. Wasmuth, H. E., M. M. Zaldivar, M. L. Berres, A. Werth, D. Scholten, S.
Hillebrandt, F. Tacke, P. Schmitz, E. Dahl, T. Wiederholt, C. Hellerbrand,
T. Berg, R. Weiskirchen, C. Trautwein, and F. Lammert. 2008. The frac-
talkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis
C infection. J. Hepatol. 48:208–215.
52. Wieland, S. F., and F. V. Chisari. 2005. Stealth and cunning: hepatitis B and
hepatitis C viruses. J. Virol. 79:9369–9380.
Downloaded from http://jvi.asm.org/ on May 24, 2017 by guest
53. Wong, G. H., and D. V. Goeddel. 1986. Tumor necrosis factors alpha and beta
inhibit virus replication and synergize with interferons. Nature 323:819–822.
54. Zhu, J., B. Min, C. J. Watson, A. Grinberg, Q. Wang, N. Killeen, J. F. Urban
Jr., L. Guo, and W. E. Paul. 2004. Conditional deletion of Gata-3 shows its
essential function in TH1-TH2 responses. Nat. Immunol. 5:1157–1165.